Abstract
Background Epithelial tubo-ovarian cancer (EOC) has high mortality partly due to late diagnosis. Prevention is available but may be associated with adverse effects. Several genetic and epidemiological risk factors (RFs) for EOC have been identified. A multifactorial risk model can help identify females at higher risk who could benefit from targeted screening and prevention.
Methods We developed an EOC risk model incorporating the effects of family history (FH), pathogenic variants (PVs) in BRCA1, BRCA2, RAD51C, RAD51D and BRIP1, a polygenic risk score (PRS) and the effects of RFs. The model was validated in a nested case-control sample of 1961 females from UKCTOCS (374 incident cases).
Results Estimated lifetime risks in the general population vary from 0.5% to 4.6% for the 1st to 99th percentiles of the EOC risk-distribution. The corresponding range for females with an affected first-degree relative is 1.9% to 10.3%. RFs provided the widest distribution followed by the PRS. In the external validation, absolute and relative 5-year risks were well-calibrated in quintiles of predicted risk.
Conclusion This multifactorial risk model can facilitate stratification, in particular among females with FH of cancer and/or moderate- and high-risk PVs. The model is available via the CanRisk Tool (www.canrisk.org).
Competing Interest Statement
The authors Douglas F. Easton, Antonis C. Antoniou, Alex P. Cunningham, Andrew Lee and Tim Carver, are listed as creators of the BOADICEA model, which has been licensed to Cambridge Enterprise for commercialisation. Usha Menon has shares in Abcodia awarded to her by UCL.
Funding Statement
This work has been supported by grants from Cancer Research UK (C12292/A20861). The analysis is part of PROMISE, which was funded through Cancer Research UK PRC Programme Grant A12677 and by The Eve Appeal. University College London investigators received support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre and from MRC core funding (MR_UU_12023). UKCTOCS was core funded by the Medical Research Council (G9901012 and G0801228), Cancer Research UK (C1479/A2884), and the Department of Health with additional support from the Eve Appeal. FMW was supported by a National Institute for Health Research (NIHR) Clinician Scientist award (NIHR CS 012 03). MT was funded by the European Union Seventh Framework Program (2007 2013)/European Research Council (310018).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was by the UK North West Multicentre Research Ethics Committees (North West MREC 00/8/34).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* joint first authors
Data Availability
The manuscript uses already published data for the development of the risk prediction model.
